New publication showing enhanced T-cell activation by targeting antibodies optimized using Attana’s QCM-technology
Attana’s long term customer Apogenix AG has published a scientific paper showing increased anti-tumor immunity in mouse studies. The achievement is based on enhanced T-cell activation by means of antibody induced immune signaling. Attana´s technology has been used in developing the antibodies.
In the paper, the research team at Apogenix AG shows data where their antibody’s interaction with both the human and mouse version of the target receptor CD27. This new antibody shows superior and consistent properties compared to a benchmark antibody. A clear and consistent dose response was observed in mouse studies. As seen in the attached figure an almost 50% reduction in tumor size was observed during the experiments.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.
Tags:
